Revenue: As of FY2025 Q2, the actual value is USD 492 K, beating the estimate of USD 169.86 K.

EPS: As of FY2025 Q2, the actual value is USD -0.06, beating the estimate of USD -0.1014.

EBIT: As of FY2025 Q2, the actual value is USD -3.568 M, beating the estimate of USD -7.322 M.

License and Other Revenue

• License and other revenue for the three months ended June 30, 2025, was $492,000, compared to $90,000 for the same period in 2024.
• For the six months ended June 30, 2025, license and other revenue was $2,822,000, compared to $320,000 for the same period in 2024.

Research and Development Expenses

• Research and development expenses for the three months ended June 30, 2025, were $1,584,000, down from $4,603,000 in the same period in 2024.
• For the six months ended June 30, 2025, these expenses were $6,047,000, compared to $10,218,000 for the same period in 2024.

General and Administrative Expenses

• General and administrative expenses for the three months ended June 30, 2025, were $2,476,000, compared to $3,077,000 for the same period in 2024.
• For the six months ended June 30, 2025, these expenses were $5,300,000, compared to $5,901,000 for the same period in 2024.

Net Loss

• Net loss for the three months ended June 30, 2025, was -$4,495,000, compared to -$7,594,000 for the same period in 2024.
• For the six months ended June 30, 2025, the net loss was -$12,718,000, compared to -$19,357,000 for the same period in 2024.

Cash Flow

• Net cash used in operating activities for the six months ended June 30, 2025, was -$10,559,000, compared to -$13,531,000 for the same period in 2024.
• Net cash used in investing activities for the six months ended June 30, 2025, was -$9,000, compared to -$11,494,000 for the same period in 2024.
• Net cash used in financing activities for the six months ended June 30, 2025, was -$76,000, compared to net cash provided by financing activities of $14,343,000 for the same period in 2024.

Future Outlook and Strategy

Core Business Focus

• Clearside Biomedical, Inc. announced plans to explore strategic alternatives to advance its SCS platform and drug development pipeline, including potential sales, licenses, or partnerships. Piper Sandler has been retained to support this strategic evaluation process.

Non-Core Business

• The company has paused all internal research and development programs during the strategic evaluation process and expects to incur approximately $2.6 million in severance and employee termination-related costs in the third quarter of 2025.

Priority

• Based on current plans and forecasted expenses, the company does not believe its cash and cash equivalents will be sufficient to fund its planned operating expenses and capital expenditure requirements for the next 12 months from the date of this filing.